Toronto, November 29, 2022 /CNW/ – HLS Therapeutics Inc. (“HLS” or the “Company”) (TSX: HLS) is a pharmaceutical company focused on the central nervous system and cardiovascular markets, Dr. Kyle Dempsey He has been appointed to the Board of Directors of the Company (the “Board”) as an independent director. Dr. Dempsey is a partner at He MVM Partners (“MVM”), a U.S.-based healthcare-focused private equity fund. Boston, Massachusetts When London, UK.
“Kyle brings significant scientific, business and investment expertise to the Board, as well as the perspective of MVM, a significant and long-term healthcare-oriented shareholder.” Greg Gubitz, Chairman of HLS. “This appointment reflects our commitment to building a strong and diverse board to help us execute our long-term growth strategy and continue to build shareholder value.”
Dr. Dempsey added: , the company has great growth potential, especially from Vascepa, due to its recently expanded redemption.I look forward to helping the company maximize its potential in the next phase of its journey. I’m here.”
During his time at MVM, Dr. Dempsey led investments and served on the boards of private and public companies including NASDAQ-listed specialty pharmaceutical company Optinose, Inc. (NASDAQ: OPTN) and GT Medical Technologies, Inc. He is also an Observer on the Board of Directors of MDxHealth SA (NASDAQ:MDXH) and previously he was an Observer on the Board of Biotheranostics, Inc. (acquired by Hologic). Prior to MVM, he was a consultant at Bain & Company, working on cases in various healthcare subsectors. Dr. Dempsey holds a Doctor of Medicine degree and his MBA. Harvard University I have a Bachelor’s Degree in Biochemistry from. Bowdoin College.
About HLS Therapeutics
Founded in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of well-established branded medicines driven in late-stage development, commercial stage in the North American market. HLS focuses on products targeting the central nervous system and cardiovascular therapeutic areas. HLS’ management team is made up of experienced pharmaceutical executives who have successfully managed products at each stage of their lifecycle in these therapeutic areas. See below for more information. www.hlstherapeutics.com
Forward-Looking Information
This release contains forward-looking statements regarding HLS and its business. Such statements are based on HLS management’s current expectations and views of future events. In some cases, forward-looking statements are “may,” “will,” “expect,” “plan,” “anticipate,” “intend,” “could,” “Estimate,” “denial of these terms, or other similar expressions intended to identify forward-looking statements, particularly as HLS pursues additional product and pipeline opportunities in certain therapeutic markets. statements regarding future growth opportunities, financial performance, and NCIB and ASPP.Future events and conditions discussed in this release are a result of known and unknown risk factors and uncertainties affecting HLS. , may not occur and may differ materially.Factors and many other factors beyond HLS’s control.Forward-looking statements and information, by their nature, are based on assumptions, known and unknown risks, uncertainties and implications of HLS’s actual results, performance or achievements or the results of the industry on future results, performance or outcomes expressed or implied by such forward-looking statements or information; Accordingly, readers should not place undue reliance on any forward-looking statements or information.A discussion of the material risks and assumptions related to this release is set forth in the company’s annual information form dated December 2018. It has been. March 16, 2022and date of management discussion and analysis November 9, 2022Both have been submitted to SEDAR and can be accessed at www.sedar.com. Accordingly, readers should not place undue reliance on forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date they are made, and HLS does not make any statements based on new information, future events, or otherwise. .
Source HLS Therapeutics Inc.
For more information, please contact Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, [email protected]
